pharmaphorum.com/news/case-st...
pharmaphorum.com/news/case-st...
https://www.statnews.com/2026/09/29/beam-therapeutics-yoltech-serapha-gene-editing-lawsuit/?utm_campaign=rss
https://www.statnews.com/2026/09/29/beam-therapeutics-yoltech-serapha-gene-editing-lawsuit/?utm_campaign=rss
$VERV #CRISPR
$VERV #CRISPR
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
@endpts.com: endpoints.news/chinese-cris...
@endpts.com: endpoints.news/chinese-cris...
By: Salong Debbarma on Monday, March 16, 2026
By: Salong Debbarma on Monday, March 16, 2026
By: Srinath on Sunday, March 15, 2026
By: Srinath on Sunday, March 15, 2026
By: Ryan Cross on Wednesday, September 10, 2025
By: Ryan Cross on Wednesday, September 10, 2025
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
endpts.com/chinese-star...
endpts.com/chinese-star...